The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 1, 2006, Pages 228-234

  Zesławska, Ewa ^a   Jacob, Uwe ^b   Stürzebecher, Jörg ^c   Oleksyn, Barbara J ^d  

^a PEDAGOGICAL UNIVERSITY   (Poland)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Crystal structure; Inhibitor; Picrate; Urokinase; X ray diffraction

Indexed keywords

N ALPHA (4 TOLUENESULFONYL) DEXTRO AMIDINOPHENYLALANYLPIPERIDINE; PICRIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN; TRYPSIN; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; COMPLEX FORMATION; CONFORMATION; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING;

AMIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM METASTASIS; PICRATES; PIPERIDINES; PROTEIN CONFORMATION; SERINE ENDOPEPTIDASES; STEREOISOMERISM; URINARY PLASMINOGEN ACTIVATOR;

EID: 27744447821     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.08.089     Document Type: Article

References (42)

1. G.A. Dudek, M. Kloczewiak, A.Z. Budzynski, Z.S. Latallo, and M. Kopec Characterisation and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin Biochim. Biophys. Acta 214 1970 44
2. L.A. Liotta, R.H. Goldfarb, R. Brundage, G.P. Siegal, V. Terranova, and S. Garbisa Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane Cancer Res. 41 1981 4629
3. D. Chain, T. Kreizman, H. Shapira, and S. Shaltiel Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1 FEBS Lett. 285 1991 251
4. E. Mochan, and T. Keler Plasmin degradation of cartilage proteoglycan Biochim. Biophys. Acta 800 1984 312
5. J.D. Vassalli, A.P. Sappino, and D. Belin The plasminogen activator/plasmin system J. Clin. Invest. 88 1991 1067
6. H.A. Chapman Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration Curr. Opin. Cell Biol. 9 1997 714
7. R. Lottenberg A novel approach to explore the role of plasminogen in bacterial pathogenesis Trends Microbiol. 5 1997 466 discussion 468
8. M. Mayer Biochemical and biological aspects of the plasminogen activation system Clin. Biochem. 23 1990 197
9. H.R. Lijnen, and D. Collen Interaction of plasminogen activators and inhibitors with plasminogen and fibrin Semin. Thromb. Hemost. 8 1982 2
10. S.A Rabbani, and R.H.M. Xing Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies Int. J. Oncol. 12 1998 911
11. J.P. Irigoyen, P. Munoz-Canoves, L. Montero, M. Koziczak, and Y. Nagamine The plasminogen activator system: biology and regulation Cell Mol. Life Sci. 56 1999 104
12. N. Sidenius, and F. Blasi The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy Cancer Metast. Rev. 22 2003 205
13. Y.H. Kook, J. Adamski, A. Zelent, and L. Ossowski The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy EMBO J. 13 1994 3983
14. C.W. Crowley, R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, and A.D. Levinson Prevention of metastasis by inhibition of the urokinase receptor Proc. Natl. Acad. Sci. USA 90 1993 5021
15. F. Fazioli, and F. Blasi Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci. 15 1994 25
16. L. Ossowski, H. Russo-Payne, and E.L. Wilson Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse Cancer Res. 51 1991 274
17. O. Wilhelm, M. Schmitt, S. Hohl, R. Senekowitsch, and H. Graeff Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice Clin. Exp. Metast. 13 1995 296
18. V. Magdolen, P. Rettenberger, M. Koppitz, L. Goretzki, H. Kessler, U.H. Weidle, B. Konig, H. Graeff, M. Schmitt, and O. Wilhelm Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator Eur. J. Biochem. 237 1996 743
19. M. Burgle, M. Koppitz, C. Riemer, H. Kessler, B. Konig, U.H. Weidle, J. Kellermann, F. Lottspeich, H. Graeff, M. Schmitt, L. Goretzki, U. Reuning, O. Wilhelm, and V. Magdolen Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides Biol. Chem. 378 1997 231
20. J. Jankun, R.W. Keck, E. Skrzypczak-Jankun, and R. Swiercz Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice [published erratum appears in Cancer Res 1998 Jan 1;58(1):179] Cancer Res. 57 1997 559
21. D. Alonso, A.M. Tejera, E.F. Farias, E. Bal de Kier Joffe, and D.E. Gomez Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428 Anticancer Res. 18 1998 4499
22. E. Zeslawska, A. Schweinitz, A. Karcher, P. Sondermann, S. Sperl, J. Sturzebecher, and U. Jacob Crystals of the urokinase type plasminogen activator variant beta c-uPA in complex with small molecule inhibitors open the way towards structure-based drug design J. Mol. Biol. 301 2000 465
23. V.L. Nienaber, D. Davidson, R. Edalji, V.L. Giranda, V. Klinghofer, J. Henkin, P. Magdalinos, R. Mantei, S. Merrick, J.M. Severin, R.A. Smith, K. Stewart, K. Walter, J.Y. Wang, M. Wendt, M. Weitzberg, X.M. Zhao, and T. Rockway Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite Struct. Fold Des. 8 2000 553
24. B.A. Katz, R. Mackman, Ch. Luong, K. Radika, A. Martelli, P.A. Sprengeler, J. Wang, H. Chan, and L. Wong Structural basis for selectivity of small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator Chem. Biol. 4 2000 299
25. B.A. Katz, K. Elrod, C. Luong, M.J. Rice, R.L. Mackman, P.A. Sprengeler, J.H. Spencer, J. Janc, J. Link, J. Litvak, R. Rai, K. Rice, S. Sideris, E. Verner, and W. Young A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site J. Mol. Biol. 307 2001 1451
26. E. Zeslawska, U. Jacob, A. Schweinitz, G. Coombs, W. Bode, and E. Madisom Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors J. Mol. Biol. 328 2003 109
27. D. Turk, J. Stürzebecher, and W. Bode Geometry of binding of the N-alpha-tosylated piperidides of m-amidino-, p-amidino- and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes FEBS Lett. 287 1991 133
28. G. Wagner, H. Horn, P. Richter, H. Vieweg, I. Lischke, and H.G. Kazimirowski Synthesis of antiproteolytically active Nα-arylsulfonylated aminophenyl- alanine amides Pharmazie 36 1981 597
29. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307
30. G.M. Sheldrick Phase annealing in SHELX-90: direct methods for larger structures Acta Cryst. A 46 1990 467
31. G.M. Sheldrick SHELXL97 1997 University of Göttingen Germany
32. L.J. Farrugia Ortep-3 for Windows-a version of ORTEP-III with a Graphical User Interface (GUI) J. Appl. Cryst. 30 1997 565
33. S. Bailey The CCP4 suite-programs for protein crystallography Acta Crystallogr. D 50 1994 760
34. T.A. Jones A graphics model building and refinement system for macromolecules J. Appl. Cryst 11 1978 268
35. A.T. Brünger Crystallography and NMR system-a new software suite for macromolecular structure determination Acta Cryst. D 54 1998 905
36. R.A. Engh, and R. Huber Accurate bond and angle parameters for X-ray protein-structure refinement Acta Cryst. A 47 1991 392
37. J. Barker, P.R. Phillips, M.G.H. Wallbridge, and H.R. Powell Benzamidine Acta Cryst. C 52 1996 2617
38. M. Jokic, M. Bajic, M. Zinic, B. Peric, and B. Kojic-Prodic Benzdiamidine Acta Cryst. C 57 2001 1354
39. A. Szumna, J. Jurczak, and Z. Urbańczyk-Lipkowska Competition between π-π stacking and hydrogen bonding in (1:2) picrates of 1,5-diamino-3-oxapentane, 1,8-diamino-3,6-dioxaoctane and 1,5-diamino-3- azapentane-solid state studies J. Mol. Struct. 526 2000 165
40. M. Renatus, W. Bode, R. Huber, J. Stürzebecher, and M.T. Stubbs Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA and urokinase J. Med. Chem. 41 1998 5445
41. M.L. Lamb, J. Tirado-Rives, and W.L. Jorgensen Estimation of the binding affinities of FKBP12 inhibitors using a linear response method Bioorg. Med. Chem. 7 1999 851
42. D.J. Diller, and L.M.J. Verlinde A critical evaluation of several global optimization algorithms for the purpose of molecular docking J. Comput. Chem. 20 1999 1740